X0306 4 2014-02-28 0 0001100962 ENDO HEALTH SOLUTIONS INC. ENDP 0001554635 Farhat Camille C/O AMERICAN MEDICAL SYSTEMS 10700 BREN ROAD WEST MINNETONKA MN 55343 0 1 0 0 President, AMS, Inc. Common Stock, par value, $.01 per share 2014-02-28 4 D 0 4031 D 0 D 2010 Stock Incentive Plan Restricted Stock Units (RSU) 2014-02-28 4 D 0 15978 D 0 D Assumed Stock Incentive Plan Restricted Stock Units (RSU) 2014-02-28 4 D 0 2195 D 0 D 2010 Stock Incentive Plan Restricted Stock Units (RSU) 2014-02-28 4 D 0 5416 D 0 D Assumed Stock Incentive Plan Performance Shares 2014-02-28 4 D 0 5854 D 0 D 2010 Stock Incentive Plan Performance Shares 2014-02-28 4 D 0 7296 D 0 D 2010 Stock Incentive Plan Performance Shares 2014-02-28 4 D 0 10832 D 0 D 2010 Stock Incentive Plan Stock Options (NQ) 32.27 2014-02-28 4 D 0 71177 D 2022-09-05 Common Stock 71177 0 D Assumed Stock Incentive Plan Stock Options (NQ) 30.80 2014-02-28 4 D 0 9697 D 2020-02-27 Common Stock 9697 0 D 2010 Stock Incentive Plan Stock Options (NQ) 79.33 2014-02-28 4 D 0 20182 D 2024-02-26 Common Stock 20182 0 D On February 28, 2014, Endo Health Solutions Inc. ("Endo") and Paladin Laboratories Inc. ("Paladin") consummated a transaction under an arrangement agreement pursuant to which each of Endo and Paladin was acquired by a new Irish holding company, Endo International plc ("New Endo"). Under the terms of the arrangement agreement (a) New Endo acquired Paladin pursuant to a plan of arrangement under Canadian law and (b) a newly formed subsidiary of New Endo merged with and into Endo, with Endo as the surviving corporation in the merger (the "Merger") and an indirect wholly owned subsidiary of New Endo. At the effective time of the Merger, each Endo common share was cancelled and converted into the right to receive one New Endo ordinary share. The number here represents shares of Endo disposed of pursuant to the Merger. These restricted stock units granted on September 5, 2012 under the 2010 Stock Incentive Plan, of which 5,327 are vested as of February 28, 2014 with the unvested portion generally vesting 25% annually at each remaining grant date anniversary through September 5, 2016, were assumed by New Endo in the Merger and converted into New Endo restricted stock units with the same terms and conditions as the original Endo restricted stock units. These restricted stock units granted on February 27, 2013 under the Assumed Stock Incentive Plan, of which 732 are vested as of February 28, 2014 with the unvested portion generally vesting 25% annually at each remaining grant date anniversary through February 27, 2017, were assumed by New Endo in the Merger and converted into New Endo restricted stock units with the same terms and conditions as the original Endo restricted stock units. These restricted stock units granted on February 26, 2014 under the 2010 Stock Incentive Plan, of which none are vested as of February 28, 2014 with the unvested portion generally vesting 25% annually at each future grant date anniversary through February 26, 2018, were assumed by New Endo in the Merger and converted into New Endo restricted stock units with the same terms and conditions as the original Endo restricted stock units. These performance share units granted on March 8, 2013 under the Assumed Stock Incentive Plan were assumed by New Endo in the Merger and converted into New Endo performance share units with the same terms and conditions as the original Endo performance share units. These performance shares vest on March 1, 2016 upon the Company achieving certain shareholder return targets over the period beginning on January 1, 2013 and ending on December 31, 2015. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable, between 0% and 300% of the target shares, will be based on achievement, as determined by the Compensation Committee of the Board of Directors of Endo, of the specified shareholder return targets over the cumulative 3-year period set forth above. These performance share units granted on July 1, 2013 under the 2010 Stock Incentive Plan were assumed by New Endo in the Merger and converted into New Endo performance share units with the same terms and conditions as the original Endo performance share units. These performance shares vest on July 1, 2016 upon the Company achieving certain financial targets over the period beginning on July 1, 2013 and ending on July 1, 2016. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable, between 0% and 300% of the target shares, will be based on achievement, as determined by the Compensation Committee of the Board of Directors of Endo, of the specified performance targets over the cumulative 3-year period set forth above. These performance share units granted on February 26, 2014 under the 2010 Stock Incentive Plan were assumed by New Endo in the Merger and converted into New Endo performance share units with the same terms and conditions as the original Endo performance share units. These performance shares vest on February 26, 2017 upon the Company achieving certain shareholder return targets over the period beginning on February 26, 2014 and ending on February 26, 2017. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable, between 0% and 300% of the target shares, will be based on achievement, as determined by the Compensation Committee of the Board of Directors of Endo, of the specified shareholder return targets over the cumulative 3-year period set forth above. These non-qualified stock options granted on September 5, 2012 under the 2010 Stock Incentive Plan, of which 17,795 are vested as of February 28, 2014 with the unvested portion generally vesting 25% per year on each remaining grant date anniversary through September 5, 2016, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options. These non-qualified stock options granted on February 27, 2013 under the Assumed Stock Incentive Plan, of which 2,425 are vested as of February 28, 2014 with the unvested portion generally vesting 25% per year on each remaining grant date anniversary through February 27, 2017, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options. These non-qualified stock options granted on February 26, 2014 under the 2010 Stock Incentive Plan, of which none are vested as of February 28, 2014 with the unvested portion generally vesting 25% per year on each grant date anniversary through February 26, 2018, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options. /s/ Caroline B. Manogue, by power of attorney 2014-03-03